RE:35% CRR on Papillary Just trying to be realistic here (I'm also invested in this stock), but you can't be the only one who has figured out the math.
I'm being cautiously optimistic which is why I'm wondering why there hasnt' been any interest from institutional investors. I had plenty of time over the last month to buy in the $0.34 range. You would think that usually everything good about the stock's potential has been priced in. If this were so good why did I have so much time to make my decision?
I've never truly gotten burned on any investment so far. But my experience with TRL has frustrated me to no end because FDA approval last May resulted in a sp up to $0.90 at one point, and after partnership + product launch, the announcements barely moved the market and it's sitting at $0.74 right now. While I"m still invested because I "know" for lack of a better word that earnings will increase the sp, it's still frustrating as hell.
I just don't want to be too overly excited and get burned. Warrents are due in september. BLA in Q2. I imagine all this is priced in. I can see a run up as we get closer to approval date but I fear we might languish at this price range for some time....